We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+1.24%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.93B
AUM Growth
-$191M
Cap. Flow
-$51.4M
Cap. Flow %
-1.75%
Top 10 Hldgs %
43.92%
Holding
115
New
17
Increased
19
Reduced
24
Closed
19

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$145M
2
IMTX icon
Immatics
IMTX
+$43.5M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$38.6M
4
KO icon
Coca-Cola
KO
+$35.8M
5
CZR icon
Caesars Entertainment
CZR
+$30.6M

Top Sells

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$78.3M
2
ACLX
Arcellx
ACLX
+$57.6M
3
RPRX icon
Royalty Pharma
RPRX
+$52.8M
4
T icon
AT&T
T
+$50.3M
5
UNH icon
UnitedHealth
UNH
+$40.7M

Sector Composition

Rank Sector Weight
1 Healthcare 55.9%
2 Consumer Discretionary 8.93%
3 Technology 8.81%
4 Financials 5.59%
5 Communication Services 4.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
1
Biohaven
BHVN
$2.16B
$210M 7.15%
5,620,271
+421,052
+8% +$19.6M
SPY icon
2
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$205M 6.99%
350,000
-200,000
-36% -$118M
ARQT icon
3
Arcutis Biotherapeutics
ARQT
$3.42B
$159M 5.41%
11,399,138
+677,627
+6% +$7.42M
ITCI
4
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$120M 4.1%
1,439,026
– –
LEGN icon
5
Legend Biotech
LEGN
$4.3B
$114M 3.88%
+3,496,234
New +$145M
BNTC icon
6
Benitec Biopharma
BNTC
$394M
$113M 3.86%
8,960,009
+130,956
+1% +$1.41M
INSM icon
7
Insmed
INSM
$23.2B
$111M 3.79%
1,611,561
-24,148
-1% -$1.74M
META icon
8
Meta Platforms (Facebook)
META
$1.51T
$99.7M 3.4%
170,338
+1,850
+1% +$1.09M
ETNB
9
DELISTED
89bio
ETNB
$79.8M 2.72%
10,202,696
+2,211,052
+28% +$18.2M
AMZN icon
10
Amazon
AMZN
$2.5T
$77.1M 2.63%
351,281
-788
-0.2% -$161K
APO icon
11
Apollo Global Management
APO
$70.7B
$76.7M 2.61%
464,140
-910
-0.2% -$144K
KO icon
12
Coca-Cola
KO
$354B
$70.8M 2.41%
1,137,853
+548,941
+93% +$35.8M
TSM icon
13
TSMC
TSM
$2.09T
$68.3M 2.33%
345,912
-2,830
-0.8% -$548K
TSLA icon
14
Tesla
TSLA
$1.24T
$66.1M 2.25%
163,630
-30,212
-16% -$9.72M
AVBP icon
15
ArriVent BioPharma
AVBP
$1.48B
$59.8M 2.04%
2,246,000
+400,838
+22% +$11.5M
EYPT icon
16
EyePoint Inc
EYPT
$1.02B
$50.5M 1.72%
6,783,091
+1,607,268
+31% +$15M
MSFT icon
17
Microsoft
MSFT
$2.84T
$49.9M 1.7%
118,397
+21,871
+23% +$9.32M
RARE icon
18
Ultragenyx Pharmaceutical
RARE
$2.65B
$48.4M 1.65%
1,151,314
– –
SBUX icon
19
Starbucks
SBUX
$118B
$47M 1.6%
514,922
-35,387
-6% -$3.42M
COF icon
20
Capital One
COF
$124B
$44.9M 1.53%
251,642
+16,042
+7% +$2.78M
KURA icon
21
Kura Oncology
KURA
$922M
$44.2M 1.51%
5,076,448
-2,576,334
-34% -$37.1M
FERG icon
22
Ferguson
FERG
$44.7B
$42.6M 1.45%
245,530
+20,320
+9% +$4.04M
GS icon
23
Goldman Sachs
GS
$313B
$42.5M 1.45%
74,198
-34,110
-31% -$19M
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$41.6M 1.42%
4,913,012
+701,007
+17% +$7.26M
AMD icon
25
Advanced Micro Devices
AMD
$851B
$40.8M 1.39%
337,415
-9,160
-3% -$1.32M
1
2 3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return

Suvretta Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Suvretta Capital Management held 115 positions worth $2.93B, down 6.1% from $3.13B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Suvretta Capital Management's Q4 2024 filing shows 17 new, 19 increased, 24 reduced and 19 closed positions. Its largest new stake was Legend Biotech: 3,496,234 shares worth $114M. The largest sale was Apple, an estimated $78.3M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Consumer Discretionary and Technology.

  • Suvretta Capital Management's largest Q4 2024 buy was Legend Biotech: 3,496,234 shares worth $114M.
  • Suvretta Capital Management added most to Coca-Cola in Q4 2024, an estimated $35.8M increase.
  • Suvretta Capital Management's biggest Q4 2024 reduction was UnitedHealth, cutting an estimated $40.7M.
  • Suvretta Capital Management fully exited Apple in Q4 2024, selling an estimated $78.3M.
  • Suvretta Capital Management's ten largest holdings make up 44% of its $2.93B portfolio in Q4 2024.
  • Suvretta Capital Management opened 17 new positions and closed 19 in Q4 2024.
  • Suvretta Capital Management's portfolio value fell 6.1% quarter-over-quarter to $2.93B.

Based on Suvretta Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.